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Human dendritic cells (DCs) infiltrate solid tumors,
but this infiltration occurs in favorable and unfa-
vorable disease prognoses. The statistical inference
is that tumor-infiltrating DCs (TIDCs) play no con-
clusive role in predicting disease progression. This
is remarkable because DCs are highly specialized
antigen-presenting cells linking innate and adap-
tive immunity. DCs either boost the immune system
(enhancing immunity) or dampen it (leading to tol-
erance). This dual effect explains the dual outcomes
of cancer progression. The reverse functional char-
acteristics of DCs depend on their maturation sta-
tus. This review elaborates on the markers used to
detect DCs in tumors. In many cases, the identifica-
tion of DCs in human cancers relies on staining for
S-100 and CD1a. These two markers are mainly ex-
pressed by Langerhans cells, which are one of sev-
eral functionally different DC subsets. The activa-
tion status of DCs is based on the expression of
CD83, DC-SIGN, and DC-LAMP, which are nonspe-
cific markers of DC maturation. The detection of
TIDCs has not kept pace with the increased knowl-
edge about the identification of DC subsets and
their maturation status. Therefore, it is difficult to
draw a conclusion about the performance of DCs in
tumors. We suggest a novel selection of markers to
distinguish human DC subsets and maturation
states. The use of these biomarkers will be of pivotal
importance to scrutinize the prognostic signifi-
cance of TIDCs. (Am J Pathol 2012, 181:733–742; http://
dx.doi.org/10.1016/j.ajpath.2012.05.012)
Cancer development follows six distinct hallmarks: the
self-production of growth hormones, imperviousness to
growth inhibitory signals, avoidance of apoptosis, unlim-
ited proliferation, sustained angiogenesis, and metastatic
capacity.1 Recently, two emerging hallmarks have beenadded to the list: the reprogramming of energy metabo-
lism and immunosurveillance evasion.2 The importance
of the latter hallmark is emphasized by a variety of opin-
ions that cancers develop either to elude an antitumor
immune response or to induce a tolerogenic response
that facilitates tumor growth, as proposed by Dunn et al3
and Zitvogel et al.4 The tumor mechanisms that subvert
the immune response include the inhibition of antigen
presentation, the inhibition of tumor resident immune
cells, and the active recruitment of suppressive immune
cells.
Tumors are infiltrated by massive amounts of innate
and adaptive immune cells, a feature that has long been
observed and studied.5 In addition, infiltrates of various
types of immune cells may be correlated with disease
prognosis, both positively and negatively.5,6 The inclu-
sion of immune cell infiltration as a routine measure of
cancer prognosis has recently been reiterated by Pagès
et al,7 although their studies focused on cells of the
adaptive arm of the immune response. The ability of
these immune effector cells to execute either an (antitu-
mor) immune response or a tolerogenic response, how-
ever, strongly depends on signals provided by antigen-
presenting cells.
Dendritic cells (DCs) are the dominant professional
antigen-presenting cells of the immune system; they are
necessary for balancing tolerance and immunity.8 DCs
constitute a diverse family of cells that reside in various
tissues and in the circulation. In addition, several studies
have shown that DCs infiltrate a vast range of human
tumors (Table 1).9–52 Moreover, the presence of DCs has
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Source
Population
(No.) Markers used DC type Location DC state Prognosis
Breast carcinoma tumors
Bell et al9 32 CD1a, langerin, CD83,
DC-LAMP, CD11c
Myeloid, LC like
Myeloid, LC like
Intratumoral
Peritumoral
Immature
Mature
NA
NA
Lespagnard et al10 143 S-100 Myeloid, LC like NA NA No correlation
Hillenbrand et al11 52 CD1a, S-100 Myeloid, LC like Intratumoral NA Good
Tsuge et al12 85 CD1a, S-100 Myeloid, LC like Intratumoral
Peritumoral
CD1a
S-100
NA
NA
Coventry et al13 40 CD1a, CMRF-44,
CMFR-56, CD83
Myeloid, LC like Tumor
stroma
Around
ductal
formations
Immature NA
Iwamoto et al14 130 CD1a, S-100, CD83 Myeloid, LC like
Myeloid, LC like
Intratumoral
Peritumoral
Immature
Mature
No correlation
Good
Coventry and
Morton15
48 CD1a Myeloid, LC like Intratumoral NA Improved
Treilleux et al16 152 CD1a, langerin, DC-
LAMP, CD123
Myeloid, LC like
Myeloid, LC like
Plasmacytoid
Intratumoral
Peritumoral
Intratumoral
Immature
Mature
Immature
No correlation
No correlation
Bad
Colorectal cancer tumors
Ambe et al17 121 S-100 Myeloid, LC
Like
Invasive
margin
Tumor
center
NA Good
Suzuki et al18 20 CD1a, CD83 Myeloid, LC like
Myeloid, LC like
Tumor
Invasive
margin
Immature
Mature
Unknown
Nakayama et al19 30 S-100 Myeloid, LC like Tumor
periphery
NA Good
Dadabayev et al20 104 S-100 Myeloid, LC like Invasive
margin
Tumor
stroma
Tumor
epithelium
NA No correlation
Sandel et al21 141 CD1a, S-100, DC-
LAMP
Myeloid, LC like
Myeloid, LC like
Invasive
margin
Tumor
stroma
Tumor
epithelium
Immature
Mature
Bad
Bad
Nagorsen et al22 40 CD1a, S-100, langerin,
CD11c, CD123, DC-
LAMP
Myeloid, LC like Tumor
stroma
Tumor
epithelium
Immature Good
Lung cancer tumors
Nakajima et al23 90 S-100 Myeloid, LC like Intratumoral NA Unknown/no
Zeid and Muller24 130 S-100 Myeloid, LC like Intratumoral NA Good
Inoshima et al25 132 S-100 Myeloid, LC like Intratumoral NA Good
Kurabayashi
et al26
69 S-100 Myeloid, LC like Intratumoral NA NA
Perrot et al27 22 CD11c, BDCA-2,
CD83, Lin-
Myeloid, LC like
Plasmacytoid
Intratumoral Immature
Immature
NA
NA
Tabarkiewicz
et al28
50 CD1c, CD19, CD123,
BDCA-2
Myeloid
Plasmacytoid
NA NA
NA
Bad
No correlation
Melanoma tumors
Vermi et al29 15 CD1a, langerin, DC-
SIGN, CD206,
BDCA-2
Myeloid, LC like
Plasmacytoid
Intratumoral
Peritumoral
Immature
Immature
NA
NA
Ladanyi et al30 82 CD1a, DC-LAMP Myeloid, LC like
Myeloid, LC like
Intratumoral
Peritumoral
Immature
Mature
Good
Good
Ovarian carcinoma tumors
Bethwaite et al31 73 S-100 Myeloid, LC like Intratumoral Immature Good
Zou et al32 ND Tumor depleted: CD3,
CD14, CD16, CD19
and CD56 pDCs
isolated:
CD4CD11c
Plasmacytoid
Plasmacytoid
Intratumoral
Peritumoral
Immature
Immature
NA
NA(table continues)
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studies have found an inverse correlation, doubting the
value of infiltrating DCs. Our current knowledge of DC
biology, however, shows that the markers historically
used to detect DCs in tumors (S-100 and CD1a) are
subset-specific rather than universal DC markers. Hence,
the early investigations in the 1970s and some more
recent studies have been biased by the availability and
choice of DC-specific markers, respectively.
This review elaborates on the markers used to detect
and characterize tumor-infiltrating DCs (TIDCs). We re-
view the reported correlations between TIDC detection
and disease prognosis. The statistical inference is that
TIDCs play no conclusive role in predicting disease pro-
gression. Our current understanding of DC biology has
Table 1. Continued
Source
Population
(No.) Markers used
Wei et al33 ND pDC sorted by
CD4CD123HLA-
DRbrightCD11c–
Pla
Labidi-Galy et al34 40 Tumor depleted: CD3,
CD8, CD11b, CD14,
CD16, CD19, CD20,
CD56, EPCAM and
glycophorin A
pDCs isolated:
BDCA4-beads
Pla
Renal cell carcinoma tumors
Thurnher et al35 17 CD80, CD83, CD86
MHC class I and II,
CD54
My
Troy et al36 14 CD1a, S-100, CD80,
CD86, CD14, CD16,
CMRF-44, CD83
My
My
Schwaab et al37 17 CD1a, CD40, CD80,
CD83, CD86, CD54,
MHC class II
My
Aso et al38 33 CD83 My
Feng et al39 ND CD1a, CD83 My
Kobayashi et al40 142 S-100, CD83, MHC
class II
My
Head and neck cancer tumors
Kerrebijn et al41 18 CD1a, S-100, MHC
class II, RFD1
My
Goldman et al42 43 CD1a, S-100 My
My
Reichert et al43 132 S-100 My
Ishigami et al44 203 S-100 My
Hartmann et al45 16 BDCA-2, CD123, MHC
class II
Pla
Liu et al46 45 CD1a, S-100, DC-
LAMP
My
My
Bladder cancer tumors
Inoue et al47 90 S-100, MHC class II My
Ayari et al48 53 CD83 My
Gastric cancer tumors
Tsujitani et al49 210 S-100 My
Ishigami et al50 165 S-100, MHC class II My
Takahashi et al51 ND S-100 My
Ishigami et al52 128 S-100, DC-LAMP My
My
NA, not available; ND, not determined.increased considerably with respect to the tumor mi-croenvironment and cancer immunotherapy. We suggest
that the application of other DC subset-specific markers
is pivotal for the acquisition of unambiguous information
about TIDCs that could explain the association between
TIDCs and cancer prognosis.
DCs Are First in Command when Regulating
Immunity
DCs are the most potent professional antigen-presenting
cells of the immune system. On infection or inflammation,
immature DCs activate and differentiate into mature DCs.
These mature DCs instruct the innate immune cells and
select antigen-specific B and T lymphocytes, activating
pe Location DC state Prognosis
toid NA Immature NA
toid NA Semimature Bad
C like NA Mature NA
C like
C like
Intratumoral
Peritumoral
Immature
Mature
NA
C like Throughout
Throughout
Immature
Mature
No correlation
No correlation
C like Peritumoral Mature No correlation
C like Intratumoral
Peritumoral
Immature (CD1a)
Mature (CD83)
No correlation
Bad
C like Intratumoral Immature (S-100)
Mature (CD83)
Improved
Good
C like Intratumoral
Peritumoral
Mature (CD1a, S-100)
Immature (CD1a, S-
100)
NA
NA
C like
C like
Intratumoral
Peritumoral
Immature
Immature (CD1a)
No correlation
Good
C like Intratumoral Immature Good
C like Intratumoral Immature Good
toid Throughout Immature NA
C like
C like
Intratumoral
Peritumoral
Immature
Mature
NA
NA
C like Intratumoral Immature Good
C like Intratumoral Mature Worse
C like Intratumoral Immature Good
C like Intratumoral Immature No correlation
C like Intratumoral Immature Good
C like
C like
Intratumoral
Peritumoral
Mature
Mature
Bad
BadDC ty
smacy
smacy
eloid, L
eloid, L
eloid, L
eloid, L
eloid, L
eloid, L
eloid, L
eloid, L
eloid, L
eloid, L
eloid, L
eloid, L
smacy
eloid, L
eloid, L
eloid, L
eloid, L
eloid, L
eloid, L
eloid, L
eloid, L
eloid, Lthem to initiate adaptive immunity.53 DCs sample and
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gest proteins, break them down into peptides, and pres-
ent them in major histocompatibility complex (MHC) mol-
ecules. The DCs are matured by danger signals derived
from aberrant processes (eg, bacteria, viruses, apoptotic
cells, and cancer peptides). After maturation, DCs mi-
grate to the lymph nodes (LNs), where they present the
peptides to T cells via MHCmolecules. Recognition of the
peptide-MHC complex (signal 1) and stimulation via co-
stimulatory molecules (signal 2) and cytokines (signal 3)
leads to the full-scale activation of immunocompetent
effector T cells. The immunologic result strongly depends
on the integration of these three signals. The resting DCs
(ie, DCs receiving inhibitory signals, such as IL-10 or
corticosteroids) provide only signal 1, leading to immune
tolerance via T-cell anergy or the induction of regulatory
T cells (Tregs). Fully matured DCs provide all three sig-
nals and induce immunity.
Despite their indispensable role in triggering an im-
mune response, DCs are a rather rare and heteroge-
neous type of immune cell. DC subtypes differ in pheno-
type and function, which partly depend on their
localization.54 Langerhans cells (LCs) are DCs found pre-
dominantly in the epidermal layers of the skin, where they
are primarily involved in the uptake and presentation of
microbial antigens. This tissue-specific subset is charac-
terized by the expression of langerin. Human peripheral
blood contains two main subtypes of DCs: the CD11c-
expressing myeloid DCs (mDCs) and the CD11c-nega-
tive plasmacytoid DCs (pDCs).55 mDCs are further char-
acterized by the expression of general myeloid markers,
such as CD13 and CD33. They lack lineage-specific
markers (CD3, CD14, CD19, and CD56), but they ex-
press high levels of MHC class II. Blood-residing mDCs
are further subdivided according to their differential sur-
face expression of CD1c (BDCA-1), CD16, and BDCA-3.
All three mDC subsets have the capacity to produce
IL-12 in response to microbial stimuli.56–58 These mDC
subsets, however, clearly differ in their expression of
surface molecules and pattern recognition receptors and
their potency to stimulate T cells.8,59,60 CD16 mDCs were
found to induce potent immune responses by their se-
cretion of tumor necrosis factor-, whereas BDCA-1
mDCs play a central role in recruiting other immune cells
via IL-8 production. BDCA3 mDCs, however, were shown
to efficiently cross-present exogenous antigen to cyto-
toxic T cells, a process that is essential for the induction
of antitumor immune responses.61 pDCs are distinctively
identified by their expression of BDCA-4, BDCA-2, and
CD123. They represent a highly specialized, naturally
occurring DC subset that plays a major role in shaping
innate and adaptive immune responses via the produc-
tion of type I interferons.62,63 pDCs promptly secrete
large amounts of type I interferons in response to un-
methylated CpG oligonucleotide motifs derived from bac-
terial and viral DNA/RNA, which they sense via the
pattern recognition receptor Toll-like receptor 9.64,65
pDC-derived type I interferons (eg, mDC-derived IL-12)
participate in T-cell priming as TH1-inducing cyto-
kines.66,67 Their heterogeneous phenotypes allow the dif-
ferent DC subsets to distinctly respond to the dangersignals they encounter in their microenvironment. Hence,
it is not merely the presence of a DC but the DC’s specific
subset type and maturation status that predicts the na-
ture of the immune response.
The Prognostic Value of TIDCs
The observation that immune cells infiltrate tumor tissue
suggests that the immune system plays a prominent role
in tumor control. Early reports of beneficial infiltration
have certainly stimulated research to clarify the role of
immune cell infiltrates in tumors. Pathologists, oncolo-
gists, and immunologists have focused on DCs because
they are the first cells to respond to antigens. The clinical
significance of TIDCs has been reported for a variety of
solid tumors, as evidenced by the correlations found
between the presence of TIDCs and clinical prognosis
(Table 1). However, the reported correlations range from
positive to negative. The density and activation state of
TIDCs can be determined by a variety of different mole-
cules, but the most widely used are S-100/CD1a and
CD83/DC-LAMP. In the case of breast carcinoma, Bell et
al9 demonstrated that immature DCs expressing CD1a
and langerin are located throughout the tumor, whereas
CD83 and DC-LAMP (mature DCs) reside in the peri-
tumoral areas. Several other studies have also found that
immature TIDCs are preferentially located intratumorally,
whereas mature TIDCs reside primarily in the peritumoral
environment (Table 1). Note that although the different
tumoral locations were not investigated in all studies,
some studies do support the correlations reported by Bell
et al.9 Most studies of breast carcinoma could not find
any clinical correlation between the infiltration of
S-100 and CD1a cells and prognosis.9–16 Three
studies report improved or positive prognostic values
(CD1a, S-100, and CD83).11,14,15 One recent study
found that immature pDCs (CD123) predict an unfavor-
able prognosis.16 Immunohistologic analyses of colo-
rectal cancer samples similarly show that TIDCs can
indicate either unfavorable21 or favorable17,19,22 prog-
noses. Moreover, the same discrepancies have been re-
ported for lung cancer,23–28 ovarian carcinoma,31–34,68
bladder cancer,47,48 and gastric cancer.49–52 In contrast,
overall positive clinical correlations between TIDCs and
prognosis were found for melanoma29,30 and head and
neck cancer.41–46
Several studies report on the concomitant depletion of
DCs in the blood in addition to their accumulation in
tumors. The malignant ascites of patients with ovarian
cancer have been found to be infiltrated by pDCs,
whereas pDCs are depleted from the circulation.69,70
These findings suggest an active recruitment of pDCs
from the blood into the tumor by chemokines secreted in
the tumor microenvironment (Figure 1). In 2001, Zou et
al32 reported that pDCs are recruited into ovarian can-
cer ascites by SDF-1. The depletion of circulating DCs in
the blood has also been observed in patients with pan-
creatic cancer71 and in patients with non–small-cell lung
cancer.28 These decreases correlate with poor patient
survival.
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TIDCs are evidently not correlated with disease progres-
sion. The various analyses, however, differ considerably
in their use of markers to detect the presence of DCs and
the discrimination of their activation status.
Histologic Markers for TIDC Characterization
The density, type, and activation state of TIDCs has been
determined with a variety of different molecules, but
S-100 and CD1a are the most widely used markers. How-
ever, after decades of research, the predictive signifi-
cance of TIDCs detected using these markers remains
unresolved.
S-100 is a small, acidic regulatory protein involved in a
wide range of cellular processes. In the early 1980s,
Cocchia et al72 reported that this protein is expressed by
LCs. Concomitantly, mature interdigitating DCs in the
LNs were shown to express S-100.73 Shortly after these
findings were published, S-100 dendritic-like cells were
found to be present in various primary and metastatic
tumors (Table 1). Moreover, for a long time, the S-100
protein was the only marker available for the evaluation of
TIDCs in tumors. The surface molecule CD1a was later
added to the armamentarium for TIDC study. Similar to
S-100, CD1a expression was originally attributed to
LCs.74 Later studies demonstrated that interstitial DCs in
the dermis and in vitro cultured monocyte-derived DCs
also express CD1a molecules75 but that none of the
blood DC subsets express S-100 or CD1a. Among the
tissue-resident and peripheral DCs, the expression of
CD1a and S-100 is restricted to LCs or to LCs and inter-
digitating DCs. In addition to the constrained specificity
of these markers for only a few DC subsets, the S-100
protein is also expressed by macrophages.74 Despitethese limitations, S-100 and CD1a are the markers most
commonly used to detect DC infiltrates in tumors.
In addition to the restrictions on subset identification,
the studies based on S-100 and/or CD1a expression
could not determine the functional status of the TIDCs.
Although CD1a was initially described as a marker for
immature DCs, different in vitro and in vivo studies have
shown that CD1a and S-100 are present in mature and
immature cells.9,15,76 Successive studies have endeav-
ored to assess the maturation status of TIDCs by staining
for CD83, a DC-specific maturation marker expressed by
all subsets.77,78 Recent investigations have focused not
only on the presence of TIDCs but also on their activation
status. The discovery of such molecules as DC-LAMP
and DC-SIGN has also garnered interest in the charac-
terization of TIDCs.79,80 DC-SIGN is expressed by imma-
ture DCs, whereas DC-LAMP is present on mature DCs.
These markers could improve the ability to distinguish the
activation state of TIDCs as a first step toward describing
their functional status and understanding their potential
immunomodulatory role. Current knowledge shows that
DC-SIGN is expressed by LCs and other tissue-resident
DCs but not by any of the blood DC subsets, indicating a
confined characterization of TIDCs.
The identification of several naturally occurring DC
subsets has prompted studies aimed at specifically de-
tecting the infiltration of tumors by the distinct subsets.81
Consequently, pDCs were found to infiltrate melano-
mas,29 ovarian carcinoma and its ascites,32,34 lung can-
cer,27,28 head and neck cancer,45 and breast carcino-
mas.16 These studies were mainly based on the
expression of BDCA-2 and/or CD123. However, CD123 is
not exclusively expressed by pDCs and, thus, requires
costaining with BDCA-2, or BDCA-4 for pDC identifica-
tion. Moreover, BDCA-2 is down-regulated on pDC mat-
Figure 1. DCs are recruited into the tumor from
the blood by different chemokines expressed or
secreted in the tumor microenvironment. When
present in the tumor, TIDCs can take up anti-
gens, become activated, and migrate to the
draining LNs to instruct T cells to mount antitu-
mor immune responses. Several soluble factors
and immune cells present in the tumor microen-
vironment can hamper the process induced by
TIDCs. Therefore, it is important to understand
which of these factors need to be targeted by
specific therapy combined with TIDC activation.
DCs are designated as immature (blue), mature
(green), and tolerogenic (red). Factors that block
recruitment, maturation, or mobilization are
noted with a red X on the arrow. M-CSF, mac-
rophage colony-stimulating factor; TGF-, trans-
forming growth factor ; VEGF, vascular endo-
thelial growth factor.uration.82 Hence, studies using this antibody will most
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addition to pDCs, BDCA-1 mDCs have also been dem-
onstrated to infiltrate solid tumors, as demonstrated by
their presence in non–small-cell lung cancer tissue.28
In summary, numerous studies have attempted to
characterize TIDCs; however, because the studies
lacked extensive analysis, it is impossible to tell whether
those TIDCs (immature and especially mature) were LCs,
interstitial DCs, mDCs, or pDCs. Based on the TIDC anal-
ysis, no valid conclusion about their role in tumorigenesis
can be drawn. However, the current situation for TIDCs is
remarkably similar to past reports for tumor-infiltrating T
cells. Based on improvements in the characterization of
several T-cell subsets, a better correlation between DCs
and progression has been envisaged. The discrimination
of CD4-positive cells in conventional CD4 T cells and
Tregs was found to be predictive in several tumors types
(particularly brain and ovarian cancer).70,83
We propose a similar approach for TIDCs and suggest
that DC subset and maturation status markers will enable
valid conclusions to be drawn about the correlations be-
tween tumor infiltration and disease outcome. To find the
required markers, one must learn about the functional
characteristics of TIDCs.
TIDC Functionality
DC tumor infiltration reflects the host system’s response
to signals provided by the tumor and its microenviron-
ment. TIDCs are thought to capture and process antigens
that are released in the tumor microenvironment and then
migrate to draining LNs, where they may mount an anti-
tumor immune response (Figure 1). In mouse models,
however, effective immune responses and the specific
activation of naive T cells have also been reported di-
rectly in the tumor.84 In their study, Thompson et al84
examined antitumor responses when T-cell migration
from the LNs is blocked chemically. They also examined
mice with a complete absence of LNs. The activation of
naive T cells in the tumor is at least partially mediated by
tumor-resident antigen-presenting cells.
In many instances, soluble factors secreted by the
tumor and its microenvironment have been reported to
create an immunosuppressive environment, thereby pre-
venting the differentiation and maturation of infiltrating
immune cells. Tumors actively recruit various immuno-
suppressive cells, including Tregs, myeloid-derived sup-
pressor cells, and tumor-associated macrophages
(TAMs).85 In response to soluble factors secreted by the
tumor, these cells secrete suppressive molecules that
recruit additional tolerogenic immune cells and inhibit the
maturation and differentiation of tumor-residing naive
cells, such as TIDCs (Figure 1).9,86,87 The role and sig-
nificance of soluble factors that influence TIDC function
and lead to tumor growth and progression have been
described extensively in excellent reviews88,89; therefore,
these issues are only briefly addressed herein. Immuno-
suppressive factors can be expressed by malignant cells
and/or other cells present at the tumor site, such as
immune, epithelial, or stromal cells. One of the mostprominent factors is most likely transforming growth fac-
tor , a cytokine that affects the proliferation, activation,
and differentiation of immune cells and inhibits antitumor
immune responses (Figure 1). IL-10 is another immuno-
suppressive molecule that has been shown to negatively
affect TIDC maturation and TIDC recruitment to the tu-
mor; moreover, it correlates positively with the generation
of tolerogenic TIDCs (Figure 1).89
Two recent articles effectively illustrate the importance
of the maturation status of immune cell that have pene-
trated the tumor. The infiltration of breast cancer by im-
mature TAMs was shown to be predictive of reduced
progression-free survival and overall survival. Accord-
ingly, the chemical inhibition of TAM infiltration into mam-
mary carcinomas slows the growth of primary tumors and
decreases metastasis in mice.90 In contrast, Beatty et
al91 showed that the activation of infiltrating macro-
phages by CD40 cross-linkage induces tumor regression
in a mouse model of pancreatic carcinoma. CD40L
(CD154) is primarily expressed by activated T cells; how-
ever, the T cells in pancreatic cancer tissue apparently
fail to express CD154. Therefore, the underlying mecha-
nism is most likely via DCs, which are the best T-cell
activators in the immune system but are unable to induce
the full activation of T cells. These studies indicate that
the influx of immune cells that remain immature in the
tumor microenvironment may even have a deleterious
effect on patient survival.
The direct immunosuppressive character of the tumor
microenvironment and the established clinical signifi-
cance of such inhibitory immune cells as Tregs and TAMs
stress the importance of an elaborate characterization of
TIDCs in terms of subset allocation and maturation status.
Discriminating TIDC Characterization
Numerous studies have strived to characterize the tumor
infiltration by DCs to understand their role in the tumor
microenvironment. Thus far, the classical markers,
namely, CD1a, S-100, CD83, and DC-SIGN, used for
TIDC identification do not reveal unambiguous correla-
tions with cancer progression. In the case of T cells, the
discovery of immune suppressive and activating subsets
and their specific detection in tumor samples provides
the field with explicit correlations. These data stress the
importance of the implications of T-cell infiltration for an
accurate prognosis.92 Moreover, this study shows the
importance of intratumoral and peritumoral immune cell
infiltration, both of which contribute to the prognosis. In
this light, we advocate the use of a more appropriate set
of markers to unequivocally determine the DC subset and
maturation status (Table 2).
Expression of the historical markers S-100 and CD1a is
restricted to only a few DC subsets. These molecules can
be used in conjunction to detect CD1a, S-100 tissue-
resident interstitial DCs. Interdigitating DCs can be char-
acterized by the coexpression of S-100 and CD11c. Ad-
ditional staining with CD11c is necessary to distinguish
S-100, CD11c, CD1a interdigitating DCs from TAMs
that are S-100, CD11c, and CD1a. LCs can be read-
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tion status of these tissue-resident DC subsets can be
determined by costaining with the activation marker
CD83 or DC-LAMP.
Blood DC subsets can be identified with several avail-
able markers. The molecules BDCA-3 and BDCA-1 rep-
resent good candidate markers for the analysis of their
respective mDC subsets. Because BDCA-1 is also ex-
pressed by B cells and LCs, additional markers (S-100
and CD11c) are needed to explicitly identify BDCA1,
CD11c, and S-100 mDCs. Costaining with CD83 or
DC-LAMP can be used to detect the maturation status of
these cells. The identification of activated BDCA-3
mDCs is more complex because this molecule becomes
up-regulated on the other matured blood DC subsets.
Hence, the BDCA3, CD83 (DC-LAMP) cells must be
negative for BDCA-1 and CD123. Immature pDCs can be
readily detected by their expression of BDCA-2. Re-
cently, the cytoplasmic protein BAD-LAMP has been re-
ported to be specifically expressed by immature human
pDCs, representing a suitable new marker.93 Importantly,
this protein is also expressed in brain tissue. BDCA-2 and
BAD-LAMP are both down-regulated when pDCs mature.
Thus, the active cells should be identified as CD123,
CD11c, CD83(DC-LAMP).
The suggested marker set for identifying tumor sub-
sets and maturation status is based on its appearance in
healthy individuals. It is plausible that the tumor microen-
vironment will disturb the normal developmental program
of a DC. Such putative aberrant expression can be de-
duced by testing their function after DCs are isolated
from the tumor tissue.
Future Perspective of the Activation of TIDCs
to Boost Antitumor Immunotherapy
Any type of immunotherapy aimed at tumor eradication
will be greatly influenced by tumor-resident and circulat-
ing (draining LN) cells and factors. Therefore, cell-based
therapies should be combined with inhibitory treatments
of the immunosuppressive tumor microenvironment,
Table 2. Markers for DC Characterization
Marker LC inDC IDC BDCA-1
Langerin I/M   
CD1a I/M I/M  
S-100 I/M  I/M 
CD11c I/M I/M I/M I/M
BDCA-1 I/M   I/M
BDCA-3    M
BDCA-2    
BDCA-4    M
CD123    I/Md
BAD-LAMP    
DC-SIGN I I  
DC-LAMP M M M M
CD83 M M M M
Proposed markers for unequivocal DC characterization are shown in
*BAD-LAMP is expressed by brain tissue.
I, immature; IDC, interdigitating DC; inDC, interstitial DC; M, mature.which should be monitored carefully. Therapies that mod-ulate Tregs have been shown to improve DC vaccination
protocols.94,95 Furthermore, data from murine and human
studies demonstrate that intratumoral injections of acti-
vated DCs act synergistically with DC vaccines delivered
in the periphery.96 These data indicate that reactivation of
tumor-resident DCs could boost peripheral vaccines.
Despite the ability of tumor-infiltrating pDCs to infiltrate
solid tumors, the immunosuppressive environment dis-
ables their ability to sense released DNA/RNA via Toll-like
receptors.97–99 Therefore, the tumor-infiltrating pDCs re-
main in an inactivated state. These findings correlate with
poor prognosis16 and are linked to the induction of
Tregs.39 Several studies have now demonstrated that
topical treatment with imiquimod (a Toll-like receptor 7
agonist) leads to enhanced pDC recruitment and type I
interferon production by resident pDCs at the tumor site,
thereby generating an inflammatory environment that re-
sults in tumor regression.100,101 The intratumoral injection
of CpG motifs (inducing Toll-like receptor 9 triggering)
also has therapeutic potential in patients with basal cell
carcinoma and melanoma skin metastases.102 Another
recent study of prostate cancer describes the presence
of tolerogenic human TIDCs, which induce suppressive
tumor-specific T cells. These TIDCs show elevated levels
of FOXO3 that coincide with suppressive genes that neg-
atively regulate T-cell function. The silencing of FOXO3
abrogates the ability of TIDC to induce suppressive ac-
tivity by T cells. Moreover, in mice, this response also
leads to the reduced expression of tolerogenic media-
tors, such as indoleamine 2,3-dioxygenase and trans-
forming growth factor , and to the enhanced expression
of costimulatory molecules and proinflammatory cyto-
kines.103 Rather than reactivating TIDCs, this strategy
focuses on reversing the balance by silencing immuno-
suppressive regulators in TIDCs. Future research should
focus on the combination of the two different strategies,
as they most likely act synergistically.
Conclusions
In recent decades, tremendous efforts have been made to
BDCA-3 mDC pDC Other immune cells
  
  
  
I/M  
  
I/M M 
 I 
 I/M 
 I/M 
 I *
  
M M 
M M mDC
im
bold.understand the tumor microenvironment and the role of
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AJP September 2012, Vol. 181, No. 3TIDCs in tumor progression. Thus far, the detection of
TIDCs does not unambiguously correlate with clinical pa-
rameters. To enable therapeutic strategies aimed at manip-
ulating TIDCs, it is necessary to fully understand their func-
tional state and to know which of the DC subsets are
present in the tumor environment and where they are lo-
cated. To obtain specific data about the presence, localiza-
tion, function, and, ultimately, role of different TIDCs, the
repertoire of surface markers that is used to distinguish
between TIDC subsets and TIDC activation needs to be
revised and updated. We anticipate that this specific infor-
mation, coupled with clinical data, will provide us with a
detailed roadmap that predicts disease progression and
therapeutic success based on the presence, localization,
and maturation status of TIDCs.
Acknowledgments
We thank Profs. Gosse J. Adema, I. Jolanda M. de Vries,
and Carl G. Figdor for their critical reading and construc-
tive suggestions.
References
1. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000,
100:57–70
2. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation.
Cell 2011, 144:646–674
3. Dunn GP, Old LJ, Schreiber RD: The three Es of cancer immunoedit-
ing. Annu Rev Immunol 2004, 22:329–360
4. Zitvogel L, Tesniere A, Kroemer G: Cancer despite immuno-
surveillance: immunoselection and immunosubversion. Nat Rev Immu-
nol 2006, 6:715–727
5. Talmadge JE, Donkor M, Scholar E: Inflammatory cell infiltration of
tumors: jekyll or Hyde. Cancer Metastasis Rev 2007, 26:373–400
6. Roxburgh CS, McMillan DC: The role of the in situ local inflammatory
response in predicting recurrence and survival in patients with pri-
mary operable colorectal cancer. Cancer Treat Rev 2012, 38:451–
466
7. Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G,
Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z,
Berger A, Fridman WH, Galon J: In situ cytotoxic and memory T cells
predict outcome in patients with early-stage colorectal cancer. J Clin
Oncol 2009, 27:5944–5951
8. Schreibelt G, Tel J, Sliepen KH, Benitez-Ribas D, Figdor CG, Adema
GJ, de Vries IJ: Toll-like receptor expression and function in human
dendritic cell subsets: implications for dendritic cell-based anti-
cancer immunotherapy. Cancer Immunol Immunother 2010, 59:
1573–1582
9. Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S,
Valladeau J, Davoust J, Palucka KA, Banchereau J: In breast car-
cinoma tissue, immature dendritic cells reside within the tumor,
whereas mature dendritic cells are located in peritumoral areas. J
Exp Med 1999, 190:1417–1426
10. Lespagnard L, Gancberg D, Rouas G, Leclercq G, de Saint-Aubain
Somerhausen N, Di Leo A, Piccart M, Verhest A, Larsimont D:
Tumor-infiltrating dendritic cells in adenocarcinomas of the breast: a
study of 143 neoplasms with a correlation to usual prognostic factors
and to clinical outcome. Int J Cancer 1999, 84:309–314
11. Hillenbrand EE, Neville AM, Coventry BJ: Immunohistochemical lo-
calization of CD1a-positive putative dendritic cells in human breast
tumours. Br J Cancer 1999, 79:940–944
12. Tsuge T, Yamakawa M, Tsukamoto M: Infiltrating dendritic/Langer-
hans cells in primary breast cancer. Breast Cancer Res Treat 2000,
59:141–152
13. Coventry BJ, Lee PL, Gibbs D, Hart DN: Dendritic cell density and
activation status in human breast cancer: CD1a, CMRF-44,
CMRF-56 and CD-83 expression. Br J Cancer 2002, 86:546–55114. Iwamoto M, Shinohara H, Miyamoto A, Okuzawa M, Mabuchi H,
Nohara T, Gon G, Toyoda M, Tanigawa N: Prognostic value of
tumor-infiltrating dendritic cells expressing CD83 in human breast
carcinomas. Int J Cancer 2003, 104:92–97
15. Coventry BJ, Morton J: CD1a-positive infiltrating-dendritic cell den-
sity and 5-year survival from human breast cancer. Br J Cancer
2003, 89:533–538
16. Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T,
Guastalla JP, Bremond A, Goddard S, Pin JJ, Barthelemy-Dubois C,
Lebecque S: Dendritic cell infiltration and prognosis of early stage
breast cancer. Clin Cancer Res 2004, 10:7466–7474
17. Ambe K, Mori M, Enjoji M: S-100 protein-positive dendritic cells in
colorectal adenocarcinomas: distribution and relation to the clinical
prognosis. Cancer 1989, 63:496–503
18. Suzuki A, Masuda A, Nagata H, Kameoka S, Kikawada Y, Ya-
makawa M, Kasajima T: Mature dendritic cells make clusters with T
cells in the invasive margin of colorectal carcinoma. J Pathol 2002,
196:37–43
19. Nakayama Y, Inoue Y, Minagawa N, Katsuki T, Nagashima N, Onit-
suka K, Tsurudome Y, Sako T, Hirata K, Nagata N, Itoh H: Relation-
ships between S-100 protein-positive cells and clinicopathological
factors in patients with colorectal cancer. Anticancer Res 2003,
23:4423–4426
20. Dadabayev AR, Sandel MH, Menon AG, Morreau H, Melief CJ,
Offringa R, van der Burg SH, Janssen-van Rhijn C, Ensink NG,
Tollenaar RA, van de Velde CJ, Kuppen PJ: Dendritic cells in colo-
rectal cancer correlate with other tumor-infiltrating immune cells.
Cancer Immunol Immunother 2004, 53:978–986
21. Sandel MH, Dadabayev AR, Menon AG, Morreau H, Melief CJ,
Offringa R, van der Burg SH, Janssen-van Rhijn CM, Ensink NG,
Tollenaar RA, van de Velde CJ, Kuppen PJ: Prognostic value of
tumor-infiltrating dendritic cells in colorectal cancer: role of matura-
tion status and intratumoral localization. Clin Cancer Res 2005,
11:2576–2582
22. Nagorsen D, Voigt S, Berg E, Stein H, Thiel E, Loddenkemper C:
Tumor-infiltrating macrophages and dendritic cells in human colo-
rectal cancer: relation to local regulatory T cells, systemic T-cell
response against tumor-associated antigens and survival. J Transl
Med 2007, 5:62
23. Nakajima T, Kodama T, Tsumuraya M, Shimosato Y, Kameya T:
S-100 protein-positive Langerhans cells in various human lung can-
cers, especially in peripheral adenocarcinomas. Virchows Arch A
Pathol Anat Histopathol 1985, 407:177–189
24. Zeid NA, Muller HK: S100 positive dendritic cells in human lung
tumors associated with cell differentiation and enhanced survival.
Pathology 1993, 25:338–343
25. Inoshima N, Nakanishi Y, Minami T, Izumi M, Takayama K, Yoshino
I, Hara N: The influence of dendritic cell infiltration and vascular
endothelial growth factor expression on the prognosis of non-small
cell lung cancer. Clin Cancer Res 2002, 8:3480–3486
26. Kurabayashi A, Furihata M, Matsumoto M, Hayashi H, Ohtsuki Y:
Distribution of tumor-infiltrating dendritic cells in human non-small
cell lung carcinoma in relation to apoptosis. Pathol Int 2004, 54:302–
310
27. Perrot I, Blanchard D, Freymond N, Isaac S, Guibert B, Pacheco Y,
Lebecque S: Dendritic cells infiltrating human non-small cell lung
cancer are blocked at immature stage. J Immunol 2007, 178:2763–
2769
28. Tabarkiewicz J, Rybojad P, Jablonka A, Rolinski J: CD1c and
CD303 dendritic cells in peripheral blood, lymph nodes and tumor
tissue of patients with non-small cell lung cancer. Oncol Rep 2008,
19:237–243
29. Vermi W, Bonecchi R, Facchetti F, Bianchi D, Sozzani S, Festa S,
Berenzi A, Cella M, Colonna M: Recruitment of immature plasmacy-
toid dendritic cells (plasmacytoid monocytes) and myeloid dendritic
cells in primary cutaneous melanomas. J Pathol 2003, 200:255–268
30. Ladanyi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A, Gaudi I,
Timar J: Density of DC-LAMP() mature dendritic cells in combina-
tion with activated T lymphocytes infiltrating primary cutaneous mel-
anoma is a strong independent prognostic factor. Cancer Immunol
Immunother 2007, 56:1459–1469
31. Bethwaite PB, Holloway LJ, Thornton A, Delahunt B: Infiltration by
immunocompetent cells in early stage invasive carcinoma of the
uterine cervix: a prognostic study. Pathology 1996, 28:321–327
Tumor-Infiltrating Dendritic Cells 741
AJP September 2012, Vol. 181, No. 332. Zou W, Machelon V, Coulomb-L’Hermin A, Borvak J, Nome F, Isaeva
T, Wei S, Krzysiek R, Durand-Gasselin I, Gordon A, Pustilnik T, Curiel
DT, Galanaud P, Capron F, Emilie D, Curiel TJ: Stromal-derived
factor-1 in human tumors recruits and alters the function of plasma-
cytoid precursor dendritic cells. Nat Med 2001, 7:1339–1346
33. Wei S, Kryczek I, Zou L, Daniel B, Cheng P, Mottram P, Curiel T,
Lange A, Zou W: Plasmacytoid dendritic cells induce CD8 regu-
latory T cells in human ovarian carcinoma. Cancer Res 2005, 65:
5020–5026
34. Labidi-Galy SI, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A,
Combes JD, Faget J, Mithieux F, Cassignol A, Tredan O, Durand I,
Menetrier-Caux C, Caux C, Blay JY, Ray-Coquard I, Bendriss-Ver-
mare N: Quantitative and functional alterations of plasmacytoid den-
dritic cells contribute to immune tolerance in ovarian cancer. Cancer
Res 2011, 71:5423–5434
35. Thurnher M, Radmayr C, Ramoner R, Ebner S, Bock G, Klocker H,
Romani N, Bartsch G: Human renal-cell carcinoma tissue contains
dendritic cells. Int J Cancer 1996, 68:1–7
36. Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN: Minimal
recruitment and activation of dendritic cells within renal cell carci-
noma. Clin Cancer Res 1998, 4:585–593
37. Schwaab T, Schned AR, Heaney JA, Cole BF, Atzpodien J, Wittke F,
Ernstoff MS: In vivo description of dendritic cells in human renal cell
carcinoma. J Urol 1999, 162:567–573
38. Aso T, Ogawa Y, Naoe M, Fukagai T, Yoshida H, Kushima M:
Immunohistochemical analysis of CD83. CD8 and CD4 positive cells
in renal cell carcinoma [in japanese]. Nihon Hinyokika Gakkai Zasshi
2004, 95:645–650
39. Feng J-W, Chen Y-R, Shi B-G, Yan D-W, Wagn J-S: Expression and
significance of tumor infiltrating dendritic cells in renal cell carci-
noma. Chin J Cancer Res 2005, 17:127–131
40. Kobayashi M, Suzuki K, Yashi M, Yuzawa M, Takayashiki N, Morita
T: Tumor infiltrating dendritic cells predict treatment response to
immmunotherapy in patients with metastatic renal cell carcinoma.
Anticancer Res 2007, 27:1137–1141
41. Kerrebijn JD, Balm AJ, Knegt PP, Meeuwis CA, Drexhage HA:
Macrophage and dendritic cell infiltration in head and neck squa-
mous-cell carcinoma: an immunohistochemical study. Cancer Im-
munol Immunother 1994, 38:31–37
42. Goldman SA, Baker E, Weyant RJ, Clarke MR, Myers JN, Lotze MT:
Peritumoral CD1a-positive dendritic cells are associated with im-
proved survival in patients with tongue carcinoma. Arch Otolaryngol
Head Neck Surg 1998, 124:641–646
43. Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL: The
number of intratumoral dendritic cells and zeta-chain expression in
T cells as prognostic and survival biomarkers in patients with oral
carcinoma. Cancer 2001, 91:2136–2147
44. Ishigami S, Natsugoe S, Matsumoto M, Okumura H, Sakita H, Na-
kashima S, Takao S, Aikou T: Clinical implications of intratumoral
dendritic cell infiltration in esophageal squamous cell carcinoma.
Oncol Rep 2003, 10:1237–1240
45. Hartmann E, Wollenberg B, Rothenfusser S, Wagner M, Wellisch D,
Mack B, Giese T, Gires O, Endres S, Hartmann G: Identification and
functional analysis of tumor-infiltrating plasmacytoid dendritic cells
in head and neck cancer. Cancer Res 2003, 63:6478–6487
46. Liu J, Lu G, Li Z, Tang F, Liu Y, Cui G: Distinct compartmental
distribution of mature and immature dendritic cells in esophageal
squamous cell carcinoma. Pathol Res Pract 2010, 206:602–606
47. Inoue K, Furihata M, Ohtsuki Y, Fujita Y: Distribution of S-100 protein-
positive dendritic cells and expression of HLA-DR antigen in transi-
tional cell carcinoma of the urinary bladder in relation to tumour
progression and prognosis. Virchows Arch A Pathol Anat Histo-
pathol 1993, 422:351–355
48. Ayari C, LaRue H, Hovington H, Decobert M, Harel F, Bergeron A,
Tetu B, Lacombe L, Fradet Y: Bladder tumor infiltrating mature
dendritic cells and macrophages as predictors of response to ba-
cillus Calmette-Guerin immunotherapy. Eur Urol 2009, 55:1386–
1395
49. Tsujitani S, Kakeji Y, Watanabe A, Kohnoe S, Maehara Y, Sugimachi
K: Infiltration of dendritic cells in relation to tumor invasion and lymph
node metastasis in human gastric cancer. Cancer 1990, 66:2012–
201650. Ishigami S, Natsugoe S, Hokita S, Xiangming C, Aridome K,
Iwashige H, Tokuda K, Nakajo A, Miyazono F, Aikou T: Intranodalantitumor immunocyte infiltration in node-negative gastric cancers.
Clin Cancer Res 2000, 6:2611–2617
51. Takahashi A, Kono K, Itakura J, Amemiya H, Feng Tang R, Iizuka H,
Fujii H, Matsumoto Y: Correlation of vascular endothelial growth
factor-C expression with tumor-infiltrating dendritic cells in gastric
cancer. Oncology 2002, 62:121–127
52. Ishigami S, Ueno S, Matsumoto M, Okumura H, Arigami T, Uchikado
Y, Setoyama T, Arima H, Sasaki K, Kitazono M, Shinchi H, Kijima Y,
Natsugoe S: Prognostic value of CD208-positive cell infiltration in
gastric cancer. Cancer Immunol Immunother 2010, 59:389–395
53. Banchereau J, Steinman RM: Dendritic cells and the control of
immunity. Nature 1998, 392:245–252
54. Ueno H, Klechevsky E, Schmitt N, Ni L, Flamar A-L, Zurawski S,
Zurawski G, Palucka K, Banchereau J, Oh S: Targeting human
dendritic cell subsets for improved vaccines. Semin Immunol 2011,
23:21–27
55. Shortman K, Liu YJ: Mouse and human dendritic cell subtypes. Nat
Rev Immunol 2002, 2:151–161
56. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A:
Specialization and complementarity in microbial molecule recogni-
tion by human myeloid and plasmacytoid dendritic cells. Eur J Im-
munol 2001, 31:3388–3393
57. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F,
Liu YJ: Subsets of human dendritic cell precursors express different
toll-like receptors and respond to different microbial antigens. J Exp
Med 2001, 194:863–869
58. Trinchieri G: Interleukin-12: a cytokine produced by antigen-pre-
senting cells with immunoregulatory functions in the generation of
T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994, 84:
4008–4027
59. Piccioli D, Tavarini S, Borgogni E, Steri V, Nuti S, Sammicheli C,
Bardelli M, Montagna D, Locatelli F, Wack A: Functional specializa-
tion of human circulating CD16 and CD1c myeloid dendritic-cell
subsets. Blood 2007, 109:5371–5379
60. MacDonald KP, Munster DJ, Clark GJ, Dzionek A, Schmitz J, Hart
DN: Characterization of human blood dendritic cell subsets. Blood
2002, 100:4512–4520
61. Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, Chen
JL, Keller AM, Joffre O, Zelenay S, Nye E, Le Moine A, Faure F,
Donckier V, Sancho D, Cerundolo V, Bonnet D, Reis E Sousa C:
Characterization of human DNGR-1 BDCA3 leukocytes as puta-
tive equivalents of mouse CD8 dendritic cells. J Exp Med 2010,
207:1261–1271
62. Liu YJ: IPC: professional type 1 interferon-producing cells and plas-
macytoid dendritic cell precursors. Annu Rev Immunol 2005, 23:
275–306
63. Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanza-
vecchia A, Colonna M: Plasmacytoid monocytes migrate to inflamed
lymph nodes and produce large amounts of type I interferon. Nat
Med 1999, 5:919–923
64. Gilliet M, Cao W, Liu YJ: Plasmacytoid dendritic cells: sensing
nucleic acids in viral infection and autoimmune diseases. Nat Rev
Immunol 2008, 8:594–606
65. Krieg AM: CpG motifs in bacterial DNA and their immune effects.
Annu Rev Immunol 2002, 20:709–760
66. Ito T, Liu YJ, Kadowaki N: Functional diversity and plasticity of
human dendritic cell subsets. Int J Hematol 2005, 81:188–196
67. Kadowaki N, Antonenko S, Lau JY, Liu YJ: Natural interferon /-
producing cells link innate and adaptive immunity. J Exp Med 2000,
192:219–226
68. Wei N, Tahan SR: S100 cell response to squamous cell carcinoma
of the lip: inverse correlation with metastasis. J Cutan Pathol 1998,
25:463–468
69. Wertel I, Polak G, Bednarek W, Barczynski B, Rolinski J, Kotarski J:
Dendritic cell subsets in the peritoneal fluid and peripheral blood of
women suffering from ovarian cancer. Cytometry B Clin Cytom 2008,
74:251–258
70. Curiel TJ, Cheng P, Mottram P, Alvarez X, Moons L, Evdemon-
Hogan M, Wei S, Zou L, Kryczek I, Hoyle G, Lackner A, Carmeliet P,
Zou W: Dendritic cell subsets differentially regulate angiogenesis in
human ovarian cancer. Cancer Res 2004, 64:5535–5538
71. Tjomsland V, Sandstrom P, Spangeus A, Messmer D, Emilsson J,
Falkmer U, Falkmer S, Magnusson KE, Borch K, Larsson M: Pancre-
atic adenocarcinoma exerts systemic effects on the peripheral
742 Karthaus et al
AJP September 2012, Vol. 181, No. 3blood myeloid and plasmacytoid dendritic cells: an indicator of
disease severity? BMC Cancer 2010, 10:87
72. Cocchia D, Michetti F, Donato R: Immunochemical and immuno-
cytochemical localization of S-100 antigen in normal human skin.
Nature 1981, 294:85–87
73. Takahashi K, Yamaguchi H, Ishizeki J, Nakajima T, Nakazato Y:
Immunohistochemical and immunoelectron microscopic localization
of S-100 protein in the interdigitating reticulum cells of the human
lymph node. Virchows Arch B Cell Pathol Incl Mol Pathol 1981,
37:125–135
74. Herlin T, Pallesen G, Kristensen T, Clausen N: Unusual immunophe-
notype displayed by histiocytes in haemophagocytic lymphohistio-
cystosis. J Clin Pathol 1987, 40:1413–1417
75. Brigl M, Brenner MB: CD1: antigen presentation and T cell function.
Annu Rev Immunol 2004, 22:817–890
76. McDermott RS, Beuvon F, Pauly M, Pallud C, Vincent-Salomon A,
Mosseri V, Pouillart P, Scholl SM: Tumor antigens and antigen-
presenting capacity in breast cancer. Pathobiology 2002, 70:324–
332
77. Sorg UR, Morse TM, Patton WN, Hock BD, Angus HB, Robinson BA,
Colls BM, Hart DN: Hodgkin’s cells express CD83, a dendritic cell
lineage associated antigen. Pathology 1997, 29:294–299
78. Zhou LJ, Tedder TF: Human blood dendritic cells selectively ex-
press CD83, a member of the immunoglobulin superfamily. J Immu-
nol 1995, 154:3821–3835
79. de Saint-Vis B, Vincent J, Vandenabeele S, Vanbervliet B, Pin JJ,
Ait-Yahia S, Patel S, Mattei MG, Banchereau J, Zurawski S, Davoust
J, Caux C, Lebecque S: A novel lysosome-associated membrane
glycoprotein, DC-LAMP, induced upon DC maturation, is transiently
expressed in MHC class II compartment. Immunity 1998, 9:325–336
80. Geijtenbeek TB, Torensma R, van Vliet SJ, van Duijnhoven GC,
Adema GJ, van Kooyk Y, Figdor CG: Identification of DC-SIGN, a
novel dendritic cell-specific ICAM-3 receptor that supports primary
immune responses. Cell 2000, 100:575–585
81. Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, Miltenyi S, Buck
DW, Schmitz J: BDCA-2, BDCA-3, and BDCA-4: three markers for
distinct subsets of dendritic cells in human peripheral blood. J Im-
munol 2000, 165:6037–6046
82. Tel J, Benitez-Ribas D, Hoosemans S, Cambi A, Adema GJ, Figdor
CG, Tacken PJ, de Vries IJ: DEC-205 mediates antigen uptake and
presentation by both resting and activated human plasmacytoid
dendritic cells. Eur J Immunol 2011, 41:1014–1023
83. Learn CA, Fecci PE, Schmittling RJ, Xie W, Karikari I, Mitchell DA,
Archer GE, Wei Z, Dressman H, Sampson JH: Profiling of CD4,
CD8, and CD4CD25CD45ROFoxP3 T cells in patients with
malignant glioma reveals differential expression of the immunologic
transcriptome compared with T cells from healthy volunteers. Clin
Cancer Res 2006, 12:7306–7315
84. Thompson ED, Enriquez HL, Fu YX, Engelhard VH: Tumor masses
support naive T cell infiltration, activation, and differentiation into
effectors. J Exp Med 2010, 207:1791–1804
85. Vasievich EA, Huang L: The suppressive tumor microenvironment: a
challenge in cancer immunotherapy. Mol Pharm 2011, 8:635–641
86. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP:
Decreased antigen presentation by dendritic cells in patients with
breast cancer. Clin Cancer Res 1997, 3:483–490
87. Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux
C, Blay JY: Inhibition of the differentiation of dendritic cells from
CD34() progenitors by tumor cells: role of interleukin-6 and mac-
rophage colony-stimulating factor. Blood 1998, 92:4778–479188. Gottfried E, Kreutz M, Mackensen A: Tumor-induced modulation of
dendritic cell function. Cytokine Growth Factor Rev 2008, 19:65–77
89. Yigit R, Massuger LF, Figdor CG, Torensma R: Ovarian cancer
creates a suppressive microenvironment to escape immune elimi-
nation. Gynecol Oncol 2010, 117:366–372
90. Denardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden
SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS,
Hwang ES, Jirstrom K, West BL, Coussens LM: Leukocyte complex-
ity predicts breast cancer survival and functionally regulates re-
sponse to chemotherapy. Cancer Discov 2011, 1:54–67
91. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR,
Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O’Dwyer PJ,
Vonderheide RH: CD40 agonists alter tumor stroma and show effi-
cacy against pancreatic carcinoma in mice and humans. Science
2011, 331:1612–1616
92. Galon J, Pages F, Marincola FM, Thurin M, Trinchieri G, Fox BA,
Gajewski TF, Ascierto PA: The immune score as a new possible
approach for the classification of cancer. J Transl Med 2012, 10:1
93. Defays A, David A, de Gassart A, De Angelis Rigotti F, Wenger T,
Camossetto V, Brousset P, Petrella T, Dalod M, Gatti E, Pierre P:
BAD-LAMP is a novel biomarker of nonactivated human plasmacy-
toid dendritic cells. Blood 2011, 118:609–617
94. Rech AJ, Vonderheide RH: Clinical use of anti-CD25 antibody da-
clizumab to enhance immune responses to tumor antigen vaccina-
tion by targeting regulatory T cells. Ann N Y Acad Sci 2009, 1174:
99–106
95. Grauer OM, Sutmuller RP, van Maren W, Jacobs JF, Bennink E,
Toonen LW, Nierkens S, Adema GJ: Elimination of regulatory T cells
is essential for an effective vaccination with tumor lysate-pulsed
dendritic cells in a murine glioma model. Int J Cancer 2008, 122:
1794–1802
96. Pellegatta S, Poliani PL, Stucchi E, Corno D, Colombo CA, Orzan F,
Ravanini M, Finocchiaro G: Intra-tumoral dendritic cells increase
efficacy of peripheral vaccination by modulation of glioma microen-
vironment. Neuro Oncol 2010, 12:377–388
97. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, Chang
B, DuramadO, Coffman RL: Nucleic acids of mammalian origin can act
as endogenous ligands for Toll-like receptors and may promote sys-
temic lupus erythematosus. J Exp Med 2005, 202:1131–1139
98. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang Y-H, Homey
B, Cao W, Wang Y-H, Su B, Nestle FO, Zal T, Mellman I, Schroder
J-M, Liu Y-J, Gilliet M: Plasmacytoid dendritic cells sense self-DNA
coupled with antimicrobial peptide. Nature 2007, 449:564–569
99. CaoW, Bover L, ChoM,Wen X, Hanabuchi S, BaoM, Rosen DB,Wang
YH, Shaw JL, Du Q, Li C, Arai N, Yao Z, Lanier LL, Liu YJ: Regulation
of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7
receptor interaction. J Exp Med 2009, 206:1603–1614
100. Dummer R, Urosevic M, Kempf W, Hoek K, Hafner J, Burg G:
Imiquimod in basal cell carcinoma: how does it work? Br J Dermatol
2003, 149(Suppl 66):57–58
101. Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA: Imiquimod
applied topically: a novel immune response modifier and new class
of drug. Int J Immunopharmacol 1999, 21:1–14
102. Hofmann MA, Kors C, Audring H, Walden P, Sterry W, Trefzer U:
Phase 1 evaluation of intralesionally injected TLR9-agonist PF-
3512676 in patients with basal cell carcinoma or metastatic mela-
noma. J Immunother 2008, 31:520–527
103. Watkins SK, Zhu Z, Riboldi E, Shafer-Weaver KA, Stagliano KE,
Sklavos MM, Ambs S, Yagita H, Hurwitz AA: FOXO3 programs
tumor-associated DCs to become tolerogenic in human and murine
prostate cancer. J Clin Invest 2011, 121:1361–1372
